Non-invasive Helicobacter Pylori Testing

Global Non-invasive Helicobacter Pylori Testing Market to Reach US$445.9 Million by 2030

The global market for Non-invasive Helicobacter Pylori Testing estimated at US$316.3 Million in the year 2024, is expected to reach US$445.9 Million by 2030, growing at a CAGR of 5.9% over the analysis period 2024-2030. Serologic Test, one of the segments analyzed in the report, is expected to record a 6.3% CAGR and reach US$250.9 Million by the end of the analysis period. Growth in the Urea Breath Test segment is estimated at 4.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$83.2 Million While China is Forecast to Grow at 5.8% CAGR

The Non-invasive Helicobacter Pylori Testing market in the U.S. is estimated at US$83.2 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$71.8 Million by the year 2030 trailing a CAGR of 5.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 5.5% and 5.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.7% CAGR.

Global Non-Invasive Helicobacter Pylori Testing Market – Key Trends & Drivers Summarized

Why Is Non-Invasive Testing Emerging as the Preferred Route for Detecting H. Pylori?

The global healthcare landscape is witnessing a profound shift in the diagnosis ofHelicobacter pylori (H. pylori) with non-invasive testing rapidly replacing traditional, invasive approaches. Historically, endoscopy with biopsy was the gold standard for identifying this gastric pathogen, but it came with considerable discomfort, higher costs, and procedural risks—especially for asymptomatic or pediatric patients. Non-invasive tests such as the urea breath test (UBT), stool antigen test (SAT), and serology are now gaining widespread clinical and commercial traction for their simplicity, speed, and patient-friendly nature. These methods allow for efficient detection without sedation, specimen collection through invasive means, or hospital-based procedures. The urea breath test, in particular, stands out due to its high accuracy, rapid turnaround time, and suitability for both initial diagnosis and post-treatment follow-up. Additionally, stool antigen tests have become widely adopted due to their reliability and ease of sample collection, especially in pediatric settings. Serological tests, while limited in post-eradication monitoring, are still widely used in low-resource settings where affordability and accessibility are paramount. The global increase in awareness of gastrointestinal health and early testing—fueled by growing concerns around gastritis, ulcers, and gastric cancers—is significantly propelling the adoption of these non-invasive solutions. In a world where healthcare providers are shifting toward value-based care, non-invasive H. pylori diagnostics offer a powerful blend of clinical efficiency and patient compliance, redefining standards in gastrointestinal disease management.

How Are Advancements in Testing Technology Enhancing Accuracy and Patient Outcomes?

Technological progress has played a central role in elevating the accuracy, accessibility, and scalability of non-invasive H. pylori diagnostics. Innovations in mass spectrometry, immunoassays, and labeled carbon isotopes have considerably improved the sensitivity and specificity of urea breath tests, allowing clinicians to detect active infections with exceptional confidence. Similarly, the development of monoclonal antibody-based stool antigen tests has enhanced diagnostic precision by minimizing false negatives and providing robust results even in low bacterial load scenarios. In recent years, advancements in sample preparation, transport media, and at-home testing kits have further expanded the reach of these diagnostics, making them more suitable for community and telehealth models. Mobile breath testing units and portable analyzers are also entering the market, enabling on-site diagnosis in rural clinics, refugee camps, and remote health settings. Furthermore, the integration of AI-driven analytics in lab-based testing environments is streamlining workflow and supporting quicker result interpretation, which is especially useful in high-throughput public health labs. Some emerging companies are even exploring breath biomarker detection using non-isotopic sensors, potentially reducing the cost and complexity of urea breath testing. Collectively, these innovations are not only raising the bar for diagnostic quality but also enabling faster treatment decisions, lowering disease progression risks, and improving patient adherence to follow-up regimens. With rapid and accurate tools now available outside of hospital walls, H. pylori testing is becoming more aligned with modern healthcare expectations—convenience, speed, and precision.

Are Shifting Public Health Priorities and Screening Initiatives Boosting Market Momentum?

Changing public health priorities and the growing emphasis on early gastrointestinal screening are key contributors to the increasing adoption of non-invasive H. pylori testing. With the bacterium implicated in a wide array of gastric disorders—including peptic ulcers, chronic gastritis, and gastric cancer—early detection and eradication have become focal points in global health strategies, especially in regions with high prevalence rates such as Asia-Pacific, Latin America, and Eastern Europe. National screening programs in countries like Japan and South Korea have already institutionalized non-invasive testing as part of routine preventive health check-ups, leading to measurable reductions in gastric cancer incidence. In Western countries, increased awareness about the link between untreated H. pylori infection and long-term gastrointestinal complications has spurred general practitioners to recommend screening even in the absence of overt symptoms. The COVID-19 pandemic has further accelerated the shift toward non-invasive diagnostics, as healthcare systems sought ways to minimize in-clinic procedures and reduce the burden on hospital infrastructure. Non-invasive tests fit seamlessly into these revised protocols, supporting home-based sample collection and contactless consultations. Additionally, health insurers and payers are increasingly recognizing the cost-effectiveness of early, non-invasive detection, and are extending reimbursement coverage to breath and stool-based tests. Non-governmental organizations and public health agencies are also funding low-cost testing initiatives in high-burden, underserved areas, reinforcing equity in access. As these programs expand and prove successful, the case for non-invasive H. pylori testing as a cornerstone of preventive gastrointestinal care becomes increasingly compelling.

What Factors Are Driving the Expansion of the Non-Invasive H. Pylori Testing Market?

The growth in the non-invasivHelicobacter pylori testing market is driven by several factors linked to technological innovation, healthcare delivery trends, changing patient preferences, and disease burden dynamics. At the technological level, rapid advancements in diagnostic platforms have led to more reliable and efficient breath and stool-based tests, making them suitable for widespread clinical and at-home use. These platforms are increasingly integrated with digital health tools, enabling result tracking, automated alerts, and seamless communication between patients and providers. On the clinical front, a growing preference for outpatient care and early diagnosis is motivating physicians to opt for non-invasive methods that minimize risk, streamline workflows, and accelerate treatment initiation. End-user demand is also being influenced by rising consumer awareness around gut health, foodborne pathogens, and the long-term risks of untreated infections. Patients, particularly in younger age groups and those with access to digital health resources, are actively seeking less invasive, more convenient testing options. In parallel, the increasing prevalence of H. pylori—driven by factors such as poor sanitation, antibiotic resistance, and changing dietary patterns—is fueling the need for scalable, cost-effective diagnostics across both developed and emerging markets. Healthcare systems under pressure to reduce costs and improve preventive care metrics are investing in screening programs that prioritize non-invasive solutions. Lastly, favorable regulatory landscapes and greater involvement from pharmaceutical companies—particularly those marketing antibiotics for eradication therapy—are encouraging widespread testing by bundling diagnostics with treatment protocols. These converging factors are ensuring strong, sustained growth in the non-invasive H. pylori testing market on a global scale.

SCOPE OF STUDY:

The report analyzes the Non-invasive Helicobacter Pylori Testing market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Test Type (Serologic Test, Urea Breath Test, Stool / Fecal Antigen Test); Method (Laboratory-based Test Method, Point of Care Test Method); End-Use (Diagnostic Laboratories End-Use, Hospitals End-Use, Clinics End-Use, Other End-Uses)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 44 Featured) -

• Abbott Laboratories
• Biohit Oyj
• Biomerica, Inc.
• Bio-Rad Laboratories, Inc.
• Cardinal Health, Inc.
• Certest Biotec S.L.
• Coris Bioconcept SPRL
• DiaSorin S.p.A.
• Exalenz Bioscience Ltd.
• Fujirebio Holdings, Inc.
• Hoffmann-La Roche Ltd
• Luminex Corporation
• Meridian Bioscience, Inc.
• Otsuka Holdings Co., Ltd.
• QIAGEN N.V.
• Quest Diagnostics Incorporated
• Quidel Corporation
• Sekisui Diagnostics, LLC
• Shenzhen Zhonghe Headway Bio-Sci & Tech Co., Ltd.
• Thermo Fisher Scientific Inc.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.